Trial Profile
The study of effects of Canagliflozin ON T2DM patients' glycemic value Reduction and On Lowering dosage of insulin therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2018
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms CONTROL
- 28 Mar 2018 Status changed from active, no longer recruiting to completed.
- 26 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 02 Jul 2015 New trial record